Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831187) titled 'Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: First Affiliated Hospital of Wenzhou Medical University
Condition:
Glioblastoma
Intervention:
Drug: Entacapone
Drug: Bevacizumab
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 1, 2026
Target Sample Size: 96
Countries of Recruitment:
China
To know more, visit https://c...